L&S Knock-Out MDG1/ DE000LX1AJ28 /
| 2024-05-16 8:08:53 AM | Chg.-0.002 | Bid4:38:31 PM | Ask4:38:31 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.050EUR | -3.85% | 0.045 Bid Size: 10,000 |
0.056 Ask Size: 10,000 |
MEDIGENE AG NA O.N. | 1.0733 EUR | 2078-12-31 | Call |
GlobeNewswire
05-15
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
GlobeNewswire
05-14
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
GlobeNewswire
05-06
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...
GlobeNewswire
05-02
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell R...
GlobeNewswire
05-02
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
GlobeNewswire
04-25
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
GlobeNewswire
04-08
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR ...
GlobeNewswire
03-28
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
03-19
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GlobeNewswire
03-06
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Pr...
GlobeNewswire
03-04
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety...
GlobeNewswire
02-29
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentia...
GlobeNewswire
02-12
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR...
GlobeNewswire
2023-11-21
Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cas...
